Liquid and tissue profiling at the same time
for >50% faster time-to-treatment
vs tissue testing alone.4,5
| Biomarker | Therapy | |
|---|---|---|
| Non-small cell lung cancer (NSCLC) | EGFR exon 19 deletions, L858R, and T790M* | TAGRISSO® (osimertinib) |
| EGFR exon 20 insertions | RYBREVANT® (amivantamab-vmjw) |
|
| KRAS G12C | LUMAKRAS™ (sotorasib) |
|
| Breast cancer | ESR1 missense mutations between codons 310-547 | ORSERDU™ (elacestrant) |
Detect guideline-recommended genomic biomarkers
across all 4 major alteration classes.1
Genes containing alterations reported by Guardant360® CDx1
| Point Mutations and InDels (Complete or Critical Exon Coverage in 74 Genes) |
|||||
|---|---|---|---|---|---|
| ΑΚΤ1 | CDH1 | FGFR2 | KRAS | NPM1 | RIT1 |
| ALK | CDK4 | FGFR3 | MAP2K1 | NRAS | ROS1 |
| APC | CDK6 | GATA3 | MAP2K2 | NTRK1 | SMAD4 |
| AR | CDK12 | GNA11 | MAPK1 | NTRK3 | SMO |
| ARAF | CDKN2A | GNAQ | MAPK3 | PDGFRA | STK11 |
| ARID1A | CTNNB1 | GNAS | MET | PIK3CA | TERT |
| ATM | DDR2 | ΗΝF1Α | MLH1 | PTEN | TP53 |
| BRAF | EGFR | HRAS | MPL | PTPN11 | TSC1 |
| BRCA1 | ERBB2 | IDH1 | MTOR | RAF1 | VHL |
| BRCA2 | ESR1 | IDH2 | MYC | RB1 | |
| CCND1 | EZH2 | JAK2 | NF1 | RET | |
| CCND2 | FBXW7 | JAK3 | NFE2L2 | RHEB | |
| CCNE1 | FGFR1 | KIT | NOTCH1 | RHOA | |
| Amplifications (18 Genes) |
|
|---|---|
| AR | FGFR1 |
| BRAF | FGFR2 |
| CCND1 | KIT |
| CCND2 | KRAS |
| CCNE1 | MET |
| CDK4 | MYC |
| CDK6 | PDGFRA |
| EGFR | PIK3CA |
| ERBB2 | RAF1 |
| Fusions
(6 Genes) |
|---|
| ALK |
| FGFR2 |
| FGFR3 |
| NTRK1 |
| RET |
| ROS1 |
Microsatellite Instability (MSI-High)
Submit a form to order a comprehensive liquid biopsy with results available in as little as 5 days.1
*The efficacy of TAGRISSO® (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative, or unknown population, and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumour biopsy cannot be obtained.1 †Reporting is enabled for pathogenic germline alterations only. Somatic alterations will not be reported. ‡Reporting is enabled for both germline and somatic alterations. Gene charts are adapted from Guardant360 CDx Technical Information.
TAGRISSO® is a registered trademark of the AstraZeneca group of companies. RYBREVANT® is a registered trademark of Janssen Biotech, Inc. ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited. LUMAKRAS™ is a trademark of Amgen Inc. ORSERDU™ is a trademark of Stemline Therapeutics, a Menarini Group Company.
References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023., 2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Updated August 11, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test, 3. Guardant Health press release. Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications. May 21, 2024. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Receives-EU-IVDR-Certification-for-Guardant360-CDx-Liquid-Biopsy-for-Tumor-Mutation-Profiling-Across-All-Solid-Cancers-and-Companion-Diagnostic-Indications/default.aspx, 4. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first-line advanced NSCLC patients. Eur J Cancer. 2022;171:44-54.doi:10.1016/j.ejca.2022.05.012., 5. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA.
